Non-motor symptoms of Parkinson’s disease: the submerged part of the iceberg
- Authors: Titova N.V.1, Chaudhuri К.R.2
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University, the Ministry of Healthcare of the Russian Federation
- National Parkinson Foundation International Centre of Excellence, King’s College London and King’s College Hospital
- Issue: Vol 11, No 4 (2017)
- Pages: 5-18
- Section: Reviews
- Submitted: 24.12.2017
- Published: 27.12.2017
- URL: https://annaly-nevrologii.com/journal/pathID/article/view/503
- DOI: https://doi.org/10.18454/ACEN.2017.4.1
- ID: 503
Cite item
Full Text
Abstract
James Parkinson, a physician from London, described the «shaking palsy» now known as Parkinson’s disease (PD) in his classic essay in 1817. Parkinson noted tremor, bradykinesia, rigidity and stooped posture as the key motor features of this condition but also drew attention to sleep dysfunction, delirium, dementia, and dysautonomia, now known to be non-motor symptoms (NMS) of PD. Inspite of their importance, NMS in PD still remain under-recognised and poorly studied. Description of neuropathological correlates of NMS, as well as the development of comprehensive tools for their assessment in the early 2000’s, such as the NMS questionnaire (NMSQuest) and scale (NMSS), helped to establish the importance of NMS in PD and their crucial link with quality of life. In many countries, NMS evaluation in PD is now a part of the good clinical practice standards. Studies of the integral role of NMS in PD clinical structure and natural history of PD led to the concept of PD as a complex combination of motor and non-motor manifestations with a long prodromal phase dominated by a number of NMS. The prodromal phase of PD is a major current research topic: NMS-associated biomarkers may help to identify subjects who are at risk of developing motor-phase PD and, potentially, are candidates for neuroprotective therapies. NMS burden grading with cut off values, which can be used as outcome measure in clinical trials in patients with PD, have been validated. The complex multi-neurotransmitter dysfunction of PD has been reported to manifest clinically as difeferent non-motor subtypes. Recognition of such subtypes may lead to the emergence of personalized and precision medicine approaches in PD.
About the authors
Natalia V. Titova
N.I. Pirogov Russian National Research Medical University, the Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: nattitova@yandex.ru
Россия, Moscow
К. Ray Chaudhuri
National Parkinson Foundation International Centre of Excellence, King’s College London and King’s College Hospital
Email: nattitova@yandex.ru
Великобритания, London
References
- Alves G., Forsaa E.B., Pedersen K.F. et al. Epidemiology of Parkinson's disease. J Neurol 2008; 255(Suppl. 5): 18-32. doi: 10.1007/s00415-008-5004-3. PMID: 18787879
- Berger K., Breteler M.M., Helmer C. et al. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; (11 Suppl 5):S24-27. PMID: 10854358
- Chaudhuri K.R., Martinez-Martin P., Schapira A.H. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916-923. doi: 10.1002/mds.20844 PMID: 16547944
- Chaudhuri K.R., Odin P., Antonini A., Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011; 17: 717-723. doi: 10.1016/j.parkreldis.2011.02.018 PMID: 21741874
- Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-376. doi: 10.1136/jnnp.2007.131045 PMID: 18344392
- Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30(12): 1591-601. doi: 10.1002/mds.26424 PMID: 26474316
- Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59(4): 591-596. doi: 10.1002/ana.20834 PMID: 16566021
- Titova N., Padmakumar C., Lewis S.J.G., Chaudhuri K.R. Parkinson’s: a syndrome rather than a disease? Journal of Neural Transmission 2017; 124: 907-914.doi: 10.1007/s00702-016-1667-6 PMID: 28028643
- Titova N., Qamar M.A., Chaudhuri K.R. Biomarkers of Parkinson’s Disease: An Introduction. Int Rev Neurobiol 2017; 132: 183-196.doi: 10.1016/bs.irn.2017.03.003 PMID: 28554407
- Postuma R.B., Iranzo A., Hogl B. et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 2015; 77: 830-839. doi: 10.1002/ana.24385 PMID: 25767079
- Berg D., Postuma R.B., Adler C.H. et al. MDS Research Criteria for Prodromal Parkinson's Disease. Mov Disord 2015; 30(12): 1600-1611.doi: 10.1002/mds.26431 PMID: 26474317
- Titova N., Qamar M.A., Chaudhuri K.R. Biomarkers of Parkinson's Disease: An Introduction. Int Rev Neurobiol 2017; 132: 183-196. doi: 10.1016/bs.irn.2017.03.003 PMID: 28554407
- Doppler K., Jentschke H.M., Schulmeyer L. et al/ Dermal phospho‑alpha‑synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 2017; 133(4): 535-545. doi: 10.1007/s00401-017-1684-z PMID: 28180961
- Zhou J., Zhang J., Lam S.P. et al. Mortality and Its Risk Factors in Patients with Rapid Eye Movement Sleep Behavior Disorder. Sleep 2016; 39(8): 1543-1550. doi: 10.5665/sleep.6016 PMID: 27306273
- Titova N., Chaudhuri K.R. Personalised medicine in Parkinson’s disease: time to be precise. Mov Disord 2017; 32(8): 1147-1154 doi: 10.1002/mds.27027 PMID: 28605054
- Katunina E., Titova N. The epidemiology of nonmotor symptoms in PD (cohort and other studies). Int Rev Neurobiol 2017; 133: 91-110. doi: 10.1016/bs.irn.2017.05.012 PMID: 28802941
- Todorova A., Jenner P., Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Practical Neurology 2014; 14: 310-322. doi: 10.1136/practneurol-2013-000741 PMID: 24699931
- Barone P., Antonini A., Colosimo C. et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641-1649.doi: 10.1002/mds.22643 PMID: 19514014
- Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-312. PMID: 10945804
- Hagell P., Nordling S., Reimer J. et al. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002; 17: 1213-1220. doi: 10.1002/mds.10262 PMID: 12465059
- Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., Chaudhuri K.R.; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399-406. doi: 10.1002/mds.23462 PMID: 21264941
- Chaudhuri KR., Martinez-Martin P., Brown RG. et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 2007; 22: 1901-1911. doi: 10.1002/mds.21596 PMID: 17674410
- Martinez-Martin P., Rodriguez-Blazquez C., Abe K. et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009; 73: 1584-1591. doi: 10.1212/WNL.0b013e3181c0d416 PMID: 19901251
- Chaudhuri K.R., Rojo J.M., Schapira A.H. et al. A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLOS ONE 2013; 8: e57221. doi: 10.1371/journal.pone.0057221 PMID: 23468940
- Chaudhuri K.R., Sauerbier A., Rojo J.M. et al. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. Parkinsonism Relat Disord 2015; 21: 287-291.doi: 10.1016/j.parkreldis.2014.12.031 PMID: 25616694
- Braak H., Del Tredici K., Rüb U. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. PMID: 12498954
- Braak H., Ghebremedhin E., Rüb U. et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134. doi: 10.1007/s00441-004-0956-9 PMID: 15338272
- Jellinger K. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) 2015; 122: 1429-1440. doi: 10.1007/s00702-015-1405-5 PMID: 25976432
- Titova N., Schapira A.H.V., Chaudhuri K.R. et al. Nonmotor Symptoms in Experimental Models of Parkinson's Disease. Int Rev Neurobiol 2017; 133: 63-89. doi: 10.1016/bs.irn.2017.05.018 PMID: 28802936
- Martinez-Martin P., Chaudhuri K.R., Rojo-Abuin J.M. et al. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol 2015; 22: 37-43. doi: 10.1111/ene.12165 PMID: 23607783
- Storch A., Schneider C.B., Wolz M. et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800-809. doi: 10.1212/WNL.0b013e318285c0ed PMID: 23365054
- Erro R., Vitale C., Amboni M. et al. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS One 2013; 8: e70244.doi: 10.1371/journal.pone.0070244 PMID: 23936396
- Pont-Sunyer C., Hotter A., Gaig C. et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015; 30: 229-237. doi: 10.1002/mds.26077 PMID: 25449044
- Sauerbier A., Jenner P., Todorova A., Chaudhuri K.R. Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord 2016; 22(1): 41-46. doi: 10.1016/j.parkreldis.2015.09.027 PMID: 26459660
- Sauerbier A., Qamar M.A., Rajah T., Chaudhuri K.R. New concepts in the pathogenesis and presentation of Parkinson's disease. Clin Med (Lond) 2016; 16: 365-370. doi: 10.7861/clinmedicine.16-4-365 PMID: 27481383
- Zis P., Martinez-Martin P., Sauerbier A. et al. Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. Eur J Neurol 2015; 22: 1145-1150. doi: 10.1111/ene.12733 PMID: 25981492
- Titova N., Jenner P., Chaudhuri K.R. The future of Parkinson’s treatment - personalised and precision medicine. European Neurological Review 2017; 12(1): 15-16.
- Pavese N., Brooks D.J. Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta 2009; 1792(7): 722-729. doi: 10.1016/j.bbadis.2008.10.003 PMID: 18992326
- Happe S., Baier P.C., Helmschmied K. et al. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson’s disease. J. Neurol 2007; 254: 1037-1043. doi: 10.1007/s00415-006-0483-6 PMID: 17351722
- Eisensehr I., Linke R., Noachtar S. et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls. Brain 2000; 123: 1155-1160. PMID: 10825354
- Sakakibara R., Shinotoh H., Uchiyama T. et al. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci 2001; 187: 55-59. PMID: 11440745
- Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314-1322. doi: 10.1093/brain/awh445 PMID: 15716302
- Bohnen N.I., Albin, R.L. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564-573. doi: 10.1016/j.bbr.2009.12.048 PMID: 20060022
- Shimada H., Hirano S., Shinotoh H. et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73(4): 273-278. doi: 10.1212/WNL.0b013e3181ab2b58 PMID: 19474411
- Gjerløff T., Fedorova T., Knudsen K. et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain 2015; 138(Pt 3): 653-663. doi: 10.1093/brain/awu369 PMID: 25539902
- Politis M., Wu K., Loane C., Kiferle L. et al. Staging of serotonergic dysfunction in Parkinson’s disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010; 40: 216-221. doi: 10.1016/j.nbd.2010.05.028 PMID: 20594979
- Pavese N., Metta V., Bose S.K. et al. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133(11): 3434-3443. doi: 10.1093/brain/awq268 PMID: 20884645
- Politis M., Wu K., Loane C. et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010; 75: 1920-1927. doi: 10.1212/WNL.0b013e3181feb2ab PMID: 21098407
- Espay A.J., LeWitt P.A., Kaufmann H. Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. Mov Disord 2014; 29(14): 1710-1719. doi: 10.1002/mds.26048 PMID: 25297066
- Seppi K., Weintraub D., Coelho M. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011: 26(3): 42-80. doi: 10.1002/mds.23884 PMID: 22021174
- Schrag A., Sauerbier A., Chaudhuri K.R. New clinical trials for nonmotor manifestations of Parkinson's disease. Mov Disord 2015; 30: 1490-1504. doi: 10.1002/mds.26415 PMID: 26371623